Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jan 2:8:212551.
doi: 10.7573/dic.212551. eCollection 2019.

Menopause hormone therapy: latest developments and clinical practice

Tomas Fait  1
Affiliations
Review

Menopause hormone therapy: latest developments and clinical practice

Tomas Fait. Drugs Context. .

Abstract

Menopause hormone therapy (MHT) is the most efficient treatment for symptoms of acute climacteric syndrome and for efficient prevention of long-term estrogen deficiency. Vaginal administration of low doses of estrogen is a therapy of choice for treatment and prevention of urogenital atrophy and its consequences. Systemic treatment may include estrogen, but an equally efficient alternative is tibolone. Nonhormonal therapy relies on phytoestrogens, black cohosh extract, and serotonin reuptake inhibitors.

Keywords: atrophic vaginitis; bazedoxifene; climacteric syndrome; menopause hormone therapy; phytoestrogens; tibolone.

PubMed Disclaimer

Conflict of interest statement

Disclosure and potential conflicts of interest: The author declares that there is no conflict of interest in preparing this article. The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the authors are available for download at http://www.drugsincontext.com/wp-content/uploads/2018/12/dic.212551-COI.pdf

References

    1. Archer DF, Baber RJ, Barlow D, et al. Updated IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health. Climacteric. 2011;14:302–320. doi: 10.3109/13697137.2011.570590. - DOI - PubMed
    1. Birkhauser MH, Panay N, Archer DF, et al. Updated recommendations for hormone replacement therapy in the peri- and postmenopause. Climacteric. 2008;11(2):108–124. doi: 10.1080/13697130801983921. - DOI - PubMed
    1. Fait T, Fialova A, Pastor Z. The use of estradiol metered-dose transdermal spray in clinical practice. Climacteric. 2018;21(6):1–5. doi: 10.1080/13697137.2018.1504916. - DOI - PubMed
    1. Lyytinen H, Pukkala E, Ylikorkala O. Breast cancer risk in postmenopausal women using estradiol-progestogen therapy. Obstet Gynecol. 2009;113(1):65–73. doi: 10.1097/AOG.0b013e31818e8cd6. - DOI - PubMed
    1. Maclennan AH, Broadbent JL, Lester S, Moore V. Oral estrogen and combined estrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev. 2004;4:CD002978. doi: 10.1002/14651858.CD002978.pub2. - DOI - PMC - PubMed